Coming soon: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
The soon available AmoyDx® FGFR1-4 NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in the FGFR1-4 genes on DNA and RNA from FFPE material. The panel covers the complete coding sequence of the four genes. As recommended in various publications (e.g. Lamarca, A. et al., 2023), the detection of FGFR gene fusions is carried out at the RNA level; unknown fusion partners can also be identified. The library is prepared using the hybrid capture method (ddCAP technology) with an optimized DNA/cDNA co-library preparation workflow, which mostly takes place in a single reaction tube.
As with all AmoyDx® NGS panels, the sequence data is analyzed locally using the AmoyDx® NGS Data Analysis System (ANDAS).
For further information, please contact us at molpath@zytomed-systems.de
1. Lamarca, A. et al. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma ESMO Open, Volume 8, Issue 6, 102049, 2023
Further topics
Exciting news!
After months of intensive work, we are pleased to announce the launch of our latest product innovation expanding the VisionArray® product family: The VisionArray® FUNGI Chip 1.0!
S3 guideline for prostate cancer was updated
In May 2024 the S3 guideline "Prostate Cancer" (version 7.0) was updated. For the first time it is recommended to sequence genes involved in homologous recombination repair (HRR), e. g. ATM, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, HDAC2 and PALB2, before initiating a systemic therapy for castration-resistant prostate cancer (mCRPC).
